Company registration number 08412464 (England and Wales)
SANSER MEDICAL LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
PAGES FOR FILING WITH REGISTRAR
SANSER MEDICAL LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 5
SANSER MEDICAL LIMITED
BALANCE SHEET
AS AT
28 FEBRUARY 2024
28 February 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
1,033
1,377
Current assets
Debtors
4
556,928
710,523
Cash at bank and in hand
11,647
32,984
568,575
743,507
Creditors: amounts falling due within one year
5
(554,742)
(603,077)
Net current assets
13,833
140,430
Total assets less current liabilities
14,866
141,807
Creditors: amounts falling due after more than one year
6
(10,068)
(20,250)
Provisions for liabilities
(518)
(518)
Net assets
4,280
121,039
Capital and reserves
Called up share capital
1,000
1,000
Profit and loss reserves
3,280
120,039
Total equity
4,280
121,039

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 28 February 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

SANSER MEDICAL LIMITED
BALANCE SHEET (CONTINUED)
AS AT
28 FEBRUARY 2024
28 February 2024
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 29 November 2024
Dr RC Patterson
Director
Company registration number 08412464 (England and Wales)
SANSER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 3 -
1
Accounting policies
Company information

Sanser Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is Clayton, Kings Drive, Caldy, Wirral, United Kingdom, CH48 2JF.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.3
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

SANSER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 4 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
-
0
1
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 March 2023 and 28 February 2024
8,117
Depreciation and impairment
At 1 March 2023
6,740
Depreciation charged in the year
344
At 28 February 2024
7,084
Carrying amount
At 28 February 2024
1,033
At 28 February 2023
1,377
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
208,458
350,707
Amounts owed by group undertakings and undertakings in which the company has a participating interest
330,775
342,121
Other debtors
17,695
17,695
556,928
710,523
SANSER MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2024
- 5 -
5
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
9,554
9,000
Trade creditors
390,726
397,186
Amounts owed to group undertakings and undertakings in which the company has a participating interest
48,447
52,447
Corporation tax
-
0
10,503
Other taxation and social security
102,493
130,420
Other creditors
3,522
3,521
554,742
603,077
6
Creditors: amounts falling due after more than one year
2024
2023
£
£
Bank loans and overdrafts
10,068
20,250
2024-02-282023-03-01false29 November 2024CCH SoftwareCCH Accounts Production 2024.210No description of principal activityDr R C Pattersonfalsefalse084124642023-03-012024-02-28084124642024-02-28084124642023-02-2808412464core:OtherPropertyPlantEquipment2024-02-2808412464core:OtherPropertyPlantEquipment2023-02-2808412464core:CurrentFinancialInstrumentscore:WithinOneYear2024-02-2808412464core:CurrentFinancialInstrumentscore:WithinOneYear2023-02-2808412464core:Non-currentFinancialInstrumentscore:AfterOneYear2024-02-2808412464core:Non-currentFinancialInstrumentscore:AfterOneYear2023-02-2808412464core:CurrentFinancialInstruments2024-02-2808412464core:CurrentFinancialInstruments2023-02-2808412464core:ShareCapital2024-02-2808412464core:ShareCapital2023-02-2808412464core:RetainedEarningsAccumulatedLosses2024-02-2808412464core:RetainedEarningsAccumulatedLosses2023-02-2808412464bus:Director12023-03-012024-02-2808412464core:FurnitureFittings2023-03-012024-02-28084124642022-03-012023-02-2808412464core:OtherPropertyPlantEquipment2023-02-2808412464core:OtherPropertyPlantEquipment2023-03-012024-02-2808412464core:WithinOneYear2024-02-2808412464core:WithinOneYear2023-02-2808412464core:Non-currentFinancialInstruments2024-02-2808412464core:Non-currentFinancialInstruments2023-02-2808412464bus:PrivateLimitedCompanyLtd2023-03-012024-02-2808412464bus:SmallCompaniesRegimeForAccounts2023-03-012024-02-2808412464bus:FRS1022023-03-012024-02-2808412464bus:AuditExemptWithAccountantsReport2023-03-012024-02-2808412464bus:FullAccounts2023-03-012024-02-28xbrli:purexbrli:sharesiso4217:GBP